May 24, 2017. The FDA should be sure that new treatments provide a real benefit to patients before they are approved. We recommend that the FDA not approve neratinib [Nerlynx] for breast cancer unless a clear benefit can be replicated, or a benefit for overall survival is demonstrated.
Read More »